News: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

59.75USD
26 Nov 2014
Price Change (% chg)

$0.41 (+0.69%)
Prev Close
$59.34
Open
$59.63
Day's High
$59.77
Day's Low
$59.35
Volume
2,589,702
Avg. Vol
2,847,249
52-wk High
$61.33
52-wk Low
$47.63

Search Stocks
Select another date:

Mon, Nov 24 2014

Merck buys rights to NewLink's experimental Ebola vaccine

- Merck & Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine against the Ebola virus.

UPDATE 2-Merck buys rights to NewLink's experimental Ebola vaccine

(Adds terms of deal, details on WHO-coordinated trials; updates share movement)

Merck buys rights to NewLink's experimental Ebola vaccine

Nov 24 - Merck & Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine.

Britain begins review to speed access to new drugs

* Innovative Medicines and MedTech Review to report in 2015

Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.

UPDATE 1-Merck's Zetia cuts heart attack, stroke risk in long-awaited study

CHICAGO, Nov 17 - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Updates with closing prices)

Regeneron drug highly effective for those who can't take statins: study

CHICAGO - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

Regeneron drug highly effective for those who can't take statins -study

CHICAGO, Nov 17 - Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck & Co's Zetia, according to data from a clinical trial presented on Monday.

ECB's Draghi helps European shares reverse early losses

* Weir hit by renewed slump in crude (Recasts, adds quotes, detail)

Select another date:

Press Releases

Search Stocks